REVIEW SCOPE
Included studies compared ESAs (epoetin or darbepoetin) plus red blood cell (RBC) transfusions as needed with RBC transfusions as needed alone for prevention or treatment of anaemia in patients with cancer. Exclusion criteria were trials of high-dose myeloablative chemotherapy plus stem-cell transplantation, those with planned sample sizes of ,100 patients or analyses including ,50 patients, or in which .20% of patients had myelodysplastic syndromes or acute leukaemia or used ESAs as preoperative treatment. Outcomes were mortality during active study periods ((28 d after end of active period) and overall survival during follow-up.
REVIEW METHODS
Medline, EMBASE/Excerpta Medica, Cochrane Library, and conference proceedings (1985 to Jan 2008) were searched for randomised controlled trials (RCTs). Manufacturers of ESAs and trialists were contacted. Individual patient data were obtained and pooled. 53 RCTs (n = 13 933 eligible for analysis, 63% women, 58% metastatic or advanced cancer) met selection criteria and had sufficient data for analysis: 38 with chemotherapy, 3 with radiotherapy, and 5 with concurrent radiation and chemotherapy. 37 RCTs were completed, 14 were stopped prematurely, and 2 were in progress.
MAIN RESULTS
Median follow-up was 4 months during the active study period and 6-8 months overall. Meta-analysis showed that ESAs increased mortality during the active study period; the reduction in survival associated with ESAs during longer follow-up was of borderline statistical significance (table) . Meta-analysis showed similar effects in the subset of chemotherapy trials, but these were not statistically significant (table) .
CONCLUSION
Erythropoiesis-stimulating agents increase mortality in patients who have cancer and anaemia or potential for anaemia.
Abstract and commentary also appear in ACP Journal Club. COMMENTARY B ohlius et al showed that ESAs increased mortality during active study periods and reduced overall survival in cancer patients. Most studies (72%) in the meta-analysis enrolled patients who were receiving chemotherapy concomitantly with ESAs. These results parallel the findings of previously published studies, 1 which led to changes in the US Food and Drug Administration package labelling of ESA products 2 3 and in treatment guidelines. 4 A black box warning added to ESA labels in 2008 states that ESAs shorten survival and increase risk of cancer progression in patients with breast, non-small-cell lung, head and neck, lymphoma, and cervical cancers. The package inserts warn that ESAs should be used only to treat anaemia in patients receiving chemotherapy; stopped when chemotherapy is completed; and given at the lowest dose that corrects anaemia. 2 3 They also state that ESAs should not be used when chemotherapy is used with curative intent, 3 regardless of the type of cancer.
ABSTRACTED FROM
Reasons for increased mortality in patients receiving ESAs are unclear but might include stimulation of erythropoietin receptors expressed on cancer cells and/or thromboembolic events associated with higher haemoglobin concentrations.
ESAs should not be used in cancer patients who have anaemia and are receiving potentially curative chemotherapy or those not receiving active chemotherapy. Anaemic patients receiving chemotherapy for palliation should have the risks and benefits of ESAs carefully explained so that they can actively participate in decisions about using ESAs.
